Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Gregory

Showing results (301-310 of 322) with videos related to

Pageof 33
Sort By:
British Journal of Haematology|June 26, 2019
Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma AllianceJoel C Wight, Mimi Yue, Colm Keane, et al.
Cancer Discovery|January 13, 2021
Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid LeukemiaStefan Bjelosevic, Emily Gruber, Andrea Newbold, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Aryl sulfonamides as selective PDE4 inhibitorsJ G Montana, G M Buckley, N Cooper, et al.
British Journal of Haematology|March 14, 2024
Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance studyKate Manos, Leonid Churilov, Andrew Grigg, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2023
Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphomaDanielle H Oh, Xiao Ma, Simon J Hogg, et al.
Targeted Oncology|October 23, 2021
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL StudyEliza A Hawkes, Tycel Phillips, Lihua Elizabeth Budde, et al.
Infection Control and Hospital Epidemiology|March 19, 2021
Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patientCarly M Hughes, Gareth P Gregory, Anna B Pierce, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 9, 2016
Bison phylogeography constrains dispersal and viability of the Ice Free Corridor in western CanadaPeter D Heintzman, Duane Froese, John W Ives, et al.
Blood Advances|December 31, 2021
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 studyGareth P Gregory, Shaji Kumar, Ding Wang, et al.
Internal Medicine Journal|March 7, 2025
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approachAditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, et al.
Pageof 33

Showing results (301-310 of 322) with videos related to

Sort By:
Pageof 33
British Journal of Haematology|June 26, 2019
Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma AllianceJoel C Wight, Mimi Yue, Colm Keane, et al.
Cancer Discovery|January 13, 2021
Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid LeukemiaStefan Bjelosevic, Emily Gruber, Andrea Newbold, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Aryl sulfonamides as selective PDE4 inhibitorsJ G Montana, G M Buckley, N Cooper, et al.
British Journal of Haematology|March 14, 2024
Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance studyKate Manos, Leonid Churilov, Andrew Grigg, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2023
Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphomaDanielle H Oh, Xiao Ma, Simon J Hogg, et al.
Targeted Oncology|October 23, 2021
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL StudyEliza A Hawkes, Tycel Phillips, Lihua Elizabeth Budde, et al.
Infection Control and Hospital Epidemiology|March 19, 2021
Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patientCarly M Hughes, Gareth P Gregory, Anna B Pierce, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 9, 2016
Bison phylogeography constrains dispersal and viability of the Ice Free Corridor in western CanadaPeter D Heintzman, Duane Froese, John W Ives, et al.
Blood Advances|December 31, 2021
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 studyGareth P Gregory, Shaji Kumar, Ding Wang, et al.
Internal Medicine Journal|March 7, 2025
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approachAditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, et al.
Pageof 33